Gassert Chad's Form 4 filing
Ani Pharmaceuticals IncANIP · filed Aug 3, 2023
- Accession no.
- 0001871002-23-000004
- Filed
- Aug 3, 2023
- Trade date
- Aug 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $1.02M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gassert ChadCIK 0001871002 | Officer (SVP - CORP. DEV. & STRATEGY) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2023 | Common Stock | SSaleDisposed | −20,000 | $51.06F2 | −$1,021,200 | 333,226 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Reflects the weighted average price of sales on August 1, 2023. The shares were sold in multiple transactions at prices ranging from $50.52 to $52.33, inclusive.
Referenced by the price of 1 transaction in Table I.